3 Reasons SUPN is Risky and 1 Stock to Buy Instead [Yahoo! Finance]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Yahoo! Finance
This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Is there a buying opportunity in Supernus Pharmaceuticals, or does it present a risk to your portfolio? Get the full breakdown from our expert analysts, it's free Why Is Supernus Pharmaceuticals Not Exciting? We're happy investors have made money, but we don't have much confidence in Supernus Pharmaceuticals. Here are three reasons you should be careful with SUPN and a stock we'd rather own. 1. Long-Term Revenue Growth Disappoints Reviewing a company's long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Supernus Pharmaceuticals grew its sales at a mediocre 5.6% compounded annual growth rate. This fell short of our benchmark for the healthcare sector. Supernus Pharmaceuticals Quarterly Revenue 2. Fe
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract [Yahoo! Finance]Yahoo! Finance
- Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Supernus Pharmaceuticals (SUPN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SUPN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> froMarketBeat
- Supernus Pharmaceuticals (SUPN) was given a new $65.00 price target by Craig Hallum.MarketBeat
- Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
SUPN
Earnings
- 2/24/26 - Miss
SUPN
Sec Filings
- 3/18/26 - Form 4
- 3/17/26 - Form 144
- 3/16/26 - Form 144
- SUPN's page on the SEC website